Jon Mcclelland Lockard

Array ( [id] => 11122026 [patent_doc_number] => 20160319000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'DRG11-RESPONSIVE (DRAGON) GENE AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/969400 [patent_app_country] => US [patent_app_date] => 2015-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 33187 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14969400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11003873 [patent_doc_number] => 20160200822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'ANTIBODIES WHICH BIND TYPE I CANNABINOID RECEPTOR/ANGIOTENSIS II RECEPTOR HETEROMERS' [patent_app_type] => utility [patent_app_number] => 14/955586 [patent_app_country] => US [patent_app_date] => 2015-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 25957 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14955586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11763033 [patent_doc_number] => 09371392 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-21 [patent_title] => 'Treatment of complex regional pain syndrome using denosumab' [patent_app_type] => utility [patent_app_number] => 14/952724 [patent_app_country] => US [patent_app_date] => 2015-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 17749 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14952724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058661 [patent_doc_number] => 20170335005 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'Anti-Endoglin Antibodies and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/520020 [patent_app_country] => US [patent_app_date] => 2015-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 50261 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15520020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10790090 [patent_doc_number] => 20160136245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'METHODS OF TREATING PAIN USING PROTEIN SOLUTIONS' [patent_app_type] => utility [patent_app_number] => 14/937241 [patent_app_country] => US [patent_app_date] => 2015-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 24669 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14937241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11275961 [patent_doc_number] => 09492432 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells' [patent_app_type] => utility [patent_app_number] => 14/934810 [patent_app_country] => US [patent_app_date] => 2015-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 89 [patent_no_of_words] => 33908 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14934810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10706860 [patent_doc_number] => 20160053007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-25 [patent_title] => 'ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY OR AUTOIMMUNE DISEASE COMPRISING ADMINISTERING SUCH ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/931149 [patent_app_country] => US [patent_app_date] => 2015-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 63 [patent_no_of_words] => 57037 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14931149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10767843 [patent_doc_number] => 20160113999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-28 [patent_title] => 'Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Prophylaxis of Heart Failure' [patent_app_type] => utility [patent_app_number] => 14/928124 [patent_app_country] => US [patent_app_date] => 2015-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 16161 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14928124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10774798 [patent_doc_number] => 20160120952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-05 [patent_title] => 'THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/919328 [patent_app_country] => US [patent_app_date] => 2015-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 69100 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14919328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001860 [patent_doc_number] => 20170306013 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'SELECTIVE NAV PROTEIN BINDERS' [patent_app_type] => utility [patent_app_number] => 15/520204 [patent_app_country] => US [patent_app_date] => 2015-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 99139 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 26 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15520204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15510285 [patent_doc_number] => 10561709 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-18 [patent_title] => Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure [patent_app_type] => utility [patent_app_number] => 15/518730 [patent_app_country] => US [patent_app_date] => 2015-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4538 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15518730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10784186 [patent_doc_number] => 20160130342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'NOVEL P2X7 EPITOPES' [patent_app_type] => utility [patent_app_number] => 14/877715 [patent_app_country] => US [patent_app_date] => 2015-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9267 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14877715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806519 [patent_doc_number] => 20160152677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'SINGLE DOMAIN TDF-RELATED COMPOUNDS AND ANALOGS THEREOF' [patent_app_type] => utility [patent_app_number] => 14/873259 [patent_app_country] => US [patent_app_date] => 2015-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 28447 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14873259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13369047 [patent_doc_number] => 20180236064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => TARGETING TGR5 TO TREAT DISEASE [patent_app_type] => utility [patent_app_number] => 15/516499 [patent_app_country] => US [patent_app_date] => 2015-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7248 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12766270 [patent_doc_number] => 20180147258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => RECOMBINANT FUSION PROTEIN FORMULATION [patent_app_type] => utility [patent_app_number] => 15/513542 [patent_app_country] => US [patent_app_date] => 2015-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14324105 [patent_doc_number] => 10293045 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Stable liquid formulations of recombinant fusion proteins [patent_app_type] => utility [patent_app_number] => 15/513537 [patent_app_country] => US [patent_app_date] => 2015-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3980 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10662320 [patent_doc_number] => 20160008464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'Methods Of Treatment Of Pterygium Using An Anti-VEGF Agent' [patent_app_type] => utility [patent_app_number] => 14/861943 [patent_app_country] => US [patent_app_date] => 2015-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9236 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14861943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10635688 [patent_doc_number] => 09353182 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Anti-DLL3 antibodies' [patent_app_type] => utility [patent_app_number] => 14/859242 [patent_app_country] => US [patent_app_date] => 2015-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 65 [patent_no_of_words] => 72418 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14859242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15245251 [patent_doc_number] => 10508138 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-17 [patent_title] => Polypeptide capable of binding to vascular endothelial growth factor, and use thereof [patent_app_type] => utility [patent_app_number] => 15/737937 [patent_app_country] => US [patent_app_date] => 2015-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 6994 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15737937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14372493 [patent_doc_number] => 20190160159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => ACETYLCHOLINE RECEPTOR-SPECIFIC IMMUNOSUPPRESSIVE COMPOSITIONS AND METHODS OF TREATMENT OF MYASTHENIA GRAVIS [patent_app_type] => utility [patent_app_number] => 15/511363 [patent_app_country] => US [patent_app_date] => 2015-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15511363 [rel_patent_id] =>[rel_patent_doc_number] =>)